Supratentorial high-grade astrocytoma and diffuse brainstem glioma: Two challenges for the pediatric oncologist

被引:152
作者
Broniscer, A [1 ]
Gajjar, A [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Neuro Oncol, Memphis, TN 38105 USA
关键词
children; gliomas; astrocytomas; high-grade; brainstem;
D O I
10.1634/theoncologist.9-2-197
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pediatric high-grade gliomas represent a heterogeneous group of tumors that accounts for 15%-20% of all pediatric central nervous system tumors. These neoplasms predominantly involve the supratentorial hemispheres or the pons, in which case the tumors are usually called diffuse brainstem gliomas. The diagnosis of supratentorial neoplasms is dependent on their histologic appearance. The maximum possible surgical resection is always attempted since the degree of surgical resection is the main prognostic factor for these patients. Older children (>3 years) with supratentorial neoplasms undergo a multimodality treatment comprised of surgical resection, radiation therapy, and chemotherapy. The addition of chemotherapy seems to improve the survival of a subset of these children, particularly those with glioblastoma multiforme. However, 2-year survival rates remain poor for children with supratentorial neoplasms, ranging from 10%-30%. The diagnosis of a diffuse brainstem glioma is based upon typical imaging, dispensing with the need for surgery in the majority of cases. Radiation therapy is the mainstay of treatment for children with diffuse brainstem gliomas. The role of chemotherapy for these children is not clear, and it is, in general, employed in the context of an investigational study. Less than 10% of children with diffuse brainstem gliomas survive 2 years. Because the outcome for patients with either type of used, these children are ideal candidates for innovative tumor is poor when standard multimodality therapy is treatment approaches.
引用
收藏
页码:197 / 206
页数:10
相关论文
共 57 条
  • [1] ALBRIGHT AL, 1993, NEUROSURGERY, V33, P1026
  • [2] Allen J, 1999, CANCER, V86, P1064, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1064::AID-CNCR24>3.0.CO
  • [3] 2-1
  • [4] Alonso M, 2001, CANCER RES, V61, P2124
  • [5] Bobola MS, 2001, CLIN CANCER RES, V7, P613
  • [6] Bouffet E, 2000, CANCER, V88, P685, DOI 10.1002/(SICI)1097-0142(20000201)88:3<685::AID-CNCR27>3.0.CO
  • [7] 2-K
  • [8] Bredel M, 1997, CLIN CANCER RES, V3, P2157
  • [9] DNA topoisomerase IIα predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas
    Bredel, M
    Pollack, JF
    Hamilton, RL
    Birner, P
    Hainfellner, JA
    Zentner, J
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (06) : 817 - 820
  • [10] Bredel M, 1999, CLIN CANCER RES, V5, P1786